
  
    
      
        Background_NNP
        
        Mycobacterium_NNP infections_NNS are_VBP frequent_JJ
        opportunistic_JJ pathogens_NNS associated_VBN with_IN the_DT acquired_VBN
        immunodeficiency_NN syndrome_NN (_( AIDS_NNP )_) ._. Its_PRP$ relative_JJ virulence_NN
        and_CC potential_JJ for_IN person-to-person_JJ transmission_NN
        distinguishes_NNS 
        Mycobacterium_NNP tuberculosis_NNS ._. Persons_NNP
        infected_VBN with_IN the_DT human_JJ immunodeficiency_NN virus_NN (_( HIV_NNP )_) are_VBP
        particularly_RB susceptible_JJ to_TO tuberculosis_NNS ,_, either_CC by_IN the_DT
        reactivation_NN of_IN latent_NN infection_NN or_CC by_IN a_DT primary_JJ infection_NN
        with_IN rapid_JJ progression_NN to_TO active_JJ disease_NN [_NN 1_CD 2_CD 3_CD 4_CD ]_NN ._. The_DT
        annual_JJ incidence_NN rate_NN of_IN tuberculosis_NNS in_IN Colombia_NNP during_IN
        1998_CD was_VBD 19_CD ._. 6_CD per_IN 100_CD ,_, 000_CD persons_NNS [_NN 5_CD ]_NN ,_, but_CC rates_NNS
        1_CD ,_, 000_CD -_: fold_VB higher_JJR have_VBP been_VBN reported_VBN in_IN some_DT
        HIV-seropositive_NNP populations_NNS [_NN 6_CD 7_CD 8_CD 9_CD 10_CD 11_CD 12_CD 13_CD 14_CD ]_NN ._.
        In_IN addition_NN ,_, disseminated_VBN infections_NNS with_IN 
        Mycobacterium_NNP avium_NN complex_JJ are_VBP
        increasingly_RB common_JJ in_IN advanced_VBD human_JJ immunodeficiency_NN
        virus_NN (_( HIV_NNP )_) disease_NN and_CC cause_VB substantial_JJ morbidity_NN [_NN 15_CD 16_CD
        ]_NN ._. Persons_NNP with_IN HIV_NNP infection_NN and_CC CD_NNP 4_CD lymphocyte_NN counts_VBZ
        less_JJR than_IN 100_CD cells_NNS /_NN mm_NN 3_CD have_VBP a_DT probability_NN of_IN 10_CD %_NN to_TO 20_CD %_NN
        per_IN year_NN of_IN developing_VBG 
        M_NNP ._. avium_NN complex_JJ disease_NN or_CC
        bacteremia_NN [_NN 17_CD 18_CD ]_NN ._. Bacteremia_NNP involving_VBG 
        M_NNP ._. avium_NN complex_JJ produces_VBZ a_DT wide_JJ
        array_NN of_IN clinical_JJ signs_NNS and_CC symptoms_NNS ,_, including_VBG wasting_NN ,_,
        fever_NN ,_, and_CC night_NN sweats_NNS ,_, and_CC is_VBZ associated_VBN with_IN decreased_VBD
        survival_NN [_NN 17_CD 18_CD 19_CD 20_CD ]_NN ._. The_DT recovery_NN of_IN mycobacteria_NN in_IN
        blood_NN cultures_NNS can_MD help_VB to_TO discover_VB bacteremia_NN that_WDT
        frequently_RB goes_VBZ unrecognized_JJ ._. We_PRP undertook_VBD a_DT prospective_JJ
        survey_NN in_IN three_CD AIDS_NNP health_NN care_NN units_NNS in_IN Bogota_NNP ,_, Colombia_NNP ,_,
        in_IN order_NN to_TO determine_VB the_DT prevalence_NN of_IN 
        Mycobacterium_NNP species_NNS in_IN HIV-infected_NNP
        patients_NNS and_CC to_TO evaluate_VB the_DT diagnostic_JJ value_NN of_IN different_JJ
        types_NNS of_IN body_NN fluids_NNS to_TO detect_VB the_DT presence_NN of_IN
        mycobacteria_NN ._.
      
      
        Methods_NNP
        
          Patients_NNS and_CC study_NN design_NN
          This_DT study_NN was_VBD a_DT multicentric_JJ prospective_JJ study_NN of_IN the_DT
          frequency_NN of_IN 
          Mycobacterium_NNP infections_NNS in_IN persons_NNS
          infected_VBN with_IN HIV_NNP ._. The_DT study_NN was_VBD conducted_VBN in_IN three_CD major_JJ
          AIDS_NNP health_NN care_NN programs_NNS of_IN Bogota_NNP (_( "_'' Hospital_NNP
          Universitario_NNP San_NNP Juan_NNP de_IN Dios_NNP "_'' ,_, "_'' Hospital_NNP Regional_NNP Simon_NNP
          Bolívar_NNP "_'' and_CC "_'' Centro_NNP Atención_NNP Básica_NNP Chapinero_NNP del_FW Seguro_NNP
          Social_NNP "_'' )_) ._. From_IN October_NNP 1999_CD to_TO March_NNP 2000_CD ,_, a_DT total_NN of_IN 289_CD
          HIV-seropositive_NNP patients_NNS were_VBD recruited_VBN ._. Most_JJS of_IN the_DT
          participants_NNS met_VBD the_DT definition_NN of_IN AIDS_NNP ,_, or_CC were_VBD in_IN
          clinical_JJ stage_NN C_NNP (_( CDC_NNP ,_, 1993_CD )_) ._. The_DT institutional_JJ review_NN
          board_NN at_IN each_DT site_NN approved_VBD the_DT study_NN ,_, and_CC each_DT
          participant_NN gave_VBD written_VBN informed_VBN consent_NN ._.
        
        
          Specimen_NNP collection_NN and_CC culture_NN media_NNS
          For_IN all_DT patients_NNS blood_NN ,_, urine_NN ,_, stool_NN and_CC sputum_NN
          samples_NNS were_VBD collected_VBN ._. In_IN brief_JJ ,_, 5_CD to_TO 8_CD mL_NN of_IN blood_NN was_VBD
          obtained_VBN in_IN previously_RB labeled_VBN Vacutainer_NNP ™_NN tubes_NNS
          containing_VBG 1_CD ._. 7_CD mL_NN of_IN heparin_NN as_IN anticoagulant_NN ._. All_DT
          patients_NNS attempts_NNS were_VBD made_VBN to_TO collect_VB two_CD paired_VBN blood_NN
          cultures_NNS samples_NNS (_( n_NN =_SYM 648_CD )_) ,_, 2_CD urine_NN cultures_NNS (_( n_NN =_SYM 497_CD )_) ,_, 2_CD
          stool_NN cultures_NNS (_( n_NN =_SYM 374_CD )_) and_CC 2_CD sputum_NN samples_NNS (_( n_NN =_SYM 101_CD )_) ._.
          In_IN one_CD patient_NN a_DT sample_NN of_IN ascitic_JJ fluid_NN ,_, and_CC in_IN other_JJ
          case_NN cerebrospinal_NN fluid_JJ (_( CSF_NNP )_) were_VBD obtained_VBN ._.
          Bacteriologic_NNP methods_NNS were_VBD used_VBN as_RB previously_RB described_VBD [_NN
          21_CD 22_CD ]_NN ._. Briefly_NNP ,_, blood_NN samples_NNS were_VBD centrifuged_JJ 15_CD min_NN
          at_IN 2_CD ,_, 000_CD g_SYM and_CC leukocytes_NNS recovered_VBN by_IN standard_JJ methods_NNS
          with_IN Ficoll-_NNP Hypaque_NNP (_( Pharmacia_NNP Fine_NNP Chemicals_NNPS ,_,
          Piscataway_NNP ,_, NJ_NNP )_) and_CC then_RB mixed_VBN with_IN a_DT lysing_VBG solution_NN
          that_WDT contained_VBD 0_CD ._. 45_CD %_NN sodium_NN deoxycholate_NN ._. After_IN manual_JJ
          mixing_VBG ,_, tubes_NNS were_VBD centrifuged_JJ at_IN 3_CD ,_, 500_CD g_SYM for_IN 30_CD minutes_NNS
          in_IN a_DT refrigerated_JJ centrifuge_NN at_IN 4_CD ,_, 000_CD g_SYM and_CC the_DT
          supernatant_NN was_VBD discarded_VBN ._. The_DT pellet_NN was_VBD resuspended_JJ ,_,
          and_CC 0_CD ._. 2_CD %_NN bovine_JJ albumin_NN was_VBD added_VBN to_TO yield_VB a_DT final_JJ volume_NN
          of_IN 2_CD ._. 5_CD mL_NN ._.
          One_CD gr_NN of_IN stool_NN samples_NNS was_VBD placed_VBN in_IN 5_CD ml_NN of_IN albumin_NN
          Dubos_NNP media_NNS and_CC mixed_JJ in_IN Vortex_NNP ™_NN for_IN 2_CD min_NN ,_, then_RB
          incubated_JJ at_IN room_NN temperature_NN overnight_JJ ._. Afterwards_RB ,_,
          equal_JJ volumes_NNS of_IN a_DT solution_NN of_IN 2_CD %_NN NaOH_NNP were_VBD mixed_JJ in_IN
          Vortex_NNP ™_NN for_IN 2_CD min_NN and_CC incubated_JJ at_IN room_NN temperature_NN in_IN
          continuos_NNS mixing_VBG for_IN 15_CD min_NN ._. Distilled_NNP water_NN was_VBD added_VBN to_TO
          complete_VB 50_CD ml_NN and_CC the_DT mixture_NN was_VBD centrifuged_JJ at_IN 6_CD ,_, 000_CD g_SYM
          for_IN 30_CD min_NN ._. One_CD drop_NN of_IN phenol_NN red_NN was_VBD added_VBN to_TO the_DT
          pellet_NN and_CC then_RB neutralized_VBN with_IN 2_CD drops_NNS of_IN HCl_NNP 2_CD N_NNP ._. The_DT
          pellet_NN was_VBD resuspended_JJ in_IN 2_CD ml_NN of_IN saline_NN solution_NN ,_, mixed_JJ
          and_CC finally_RB 0_CD ._. 2_CD ml_NN used_VBN for_IN culture_NN ._.
          Urine_NNP samples_NNS were_VBD mixed_JJ in_IN a_DT ratio_NN of_IN 3_CD :_: 1_CD with_IN a_DT
          solution_NN of_IN 20_CD %_NN Na_NNP 
          3_CD PO_NNP 
          4_CD ._. 12_CD H_NNP 
          2_CD O_NNP ._. The_DT mixture_NN was_VBD incubated_JJ at_IN room_NN
          temperature_NN for_IN 2_CD h_NN and_CC then_RB centrifuged_JJ at_IN 6_CD ,_, 000_CD g_SYM for_IN
          30_CD min_NN ._. The_DT pellet_NN was_VBD used_VBN for_IN culture_NN after_IN being_VBG
          decontaminated_VBN by_IN Ogawa-_NNP Kudoh_NNP method_NN ._. Briefly_NNP ,_, sterile_JJ
          slabs_NNS were_VBD placed_VBN in_IN a_DT solution_NN of_IN 4_CD %_NN NaOH_NNP during_IN 1_CD or_CC 2_CD
          min_NN and_CC then_RB used_VBN to_TO culture_NN samples_NNS ._.
          Sputum_NNP was_VBD mixed_JJ in_IN equal_JJ volume_NN with_IN a_DT solution_NN of_IN 4_CD %_NN
          Na_NNP 
          3_CD PO_NNP 
          4_CD ._. 12_CD H_NNP 
          2_CD O_NNP ,_, incubated_JJ at_IN room_NN temperature_NN
          during_IN 2_CD h_NN and_CC centrifuged_JJ at_IN 6_CD ,_, 000_CD g_SYM for_IN 30_CD min_NN ._. The_DT
          pellet_NN was_VBD decontaminated_VBN by_IN the_DT Ogawa-_NNP Kudoh_NNP method_NN ,_, as_IN
          described_VBN above_IN ,_, and_CC used_VBD for_IN culture_NN ._. The_DT same_JJ procedure_NN
          was_VBD used_VBN for_IN the_DT ascitic_JJ fluid_JJ and_CC CSF_NNP samples_NNS ._.
          All_DT samples_NNS were_VBD placed_VBN in_IN 2_CD tubes_NNS with_IN a_DT biphasic_JJ
          medium_NN :_: a_DT solid_JJ phase_NN Ogawa-_NNP Kudoh_NNP with_IN iron_NN citrate_NN and_CC a_DT
          liquid_JJ phase_NN of_IN Sauton_NNP Twen_NNP albumin_NN modified_VBN medium_NN and_CC 2_CD
          tubes_NNS with_IN Stonebrink-_NNP Giraldo_NNP medium_NN ._. Readings_NNP were_VBD made_VBN
          after_IN day_NN 6_CD and_CC at_IN 2_CD ,_, 4_CD ,_, 6_CD ,_, 8_CD ,_, 12_CD and_CC 16_CD week_NN ._. A_DT positive_JJ
          culture_NN was_VBD identified_VBN following_VBG the_DT criteria_NNS of_IN the_DT
          Centers_NNPS for_IN Prevention_NNP and_CC Disease_NNP Control_NNP (_( CDC_NNP )_) [_NN 22_CD ]_NN ._.
          Resistance_NNP assay_NN was_VBD applied_VBN at_IN all_DT 
          Mycobacterium_NNP tuberculosis_NNS isolates_VBZ
          using_VBG the_DT proportion_NN method_NN for_IN streptomycin_NN (_( S_NNP )_) ,_,
          isoniazide_NN (_( H_NNP )_) ,_, thioacetazone_NN (_( Tb_NNP )_) ,_, ethambutol_NN (_( E_NNP )_) and_CC
          rifampicin_NN (_( R_NN )_) ._.
          All_DT samples_NNS were_VBD stained_JJ and_CC examined_VBD for_IN AFB_NNP after_IN
          centrifugation_NN ._.
        
        
          Statistical_NNP analysis_NN
          Statistical_NNP significance_NN for_IN comparison_NN of_IN rates_NNS was_VBD
          determined_VBN by_IN an_DT exact_JJ test_NN when_WRB sample_NN sizes_NNS were_VBD
          insufficient_JJ and_CC by_IN an_DT asymptotic_JJ test_NN when_WRB sizes_NNS were_VBD
          sufficient_JJ ._. All_DT tests_NNS were_VBD two-sided_JJ ,_, and_CC a_DT P_NN value_NN of_IN
          0_CD ._. 05_CD was_VBD considered_VBN significant_JJ ._. Exact_JJ 95_CD %_NN confidence_NN
          intervals_NNS (_( CI_NNP )_) were_VBD calculated_VBN for_IN rates_NNS by_IN assuming_VBG the_DT
          numerator_NN to_TO be_VB a_DT Poisson_NNP variable_JJ [_NN 23_CD ]_NN and_CC for_IN rate_NN
          ratios_NNS using_VBG a_DT modified_VBN binomial_NN model_NN [_NN 24_CD ]_NN ._. Adjusted_NNP
          rate_NN ratios_NNS for_IN comparisons_NNS among_IN groups_NNS defined_VBN by_IN
          demographic_JJ variables_NNS were_VBD calculated_VBN by_IN using_VBG a_DT
          Mantel-_NNP Haenszel_NNP type_NN estimator_NN for_IN incidence-rate_JJ data_NNS
          with_IN approximate_JJ 95_CD %_NN confidence_NN limits_NNS based_VBN on_IN the_DT tests_NNS
          [_NN 23_CD ]_NN ._.
        
      
      
        Results_NNS
        
          Demographic_NNP characteristics_NNS
          In_IN total_JJ ,_, 286_CD patients_NNS were_VBD studied_VBN ,_, 251_CD (_( 87_CD ._. 8_CD %_NN )_) were_VBD
          men_NNS ,_, and_CC 35_CD (_( 12_CD ._. 2_LS %_NN )_) were_VBD women_NNS ._. The_DT men_NNS :_: women_NNS ratio_NN was_VBD
          7_CD :_: 1_CD ._. The_DT age_NN range_NN was_VBD 3_CD to_TO 78_CD years_NNS with_IN a_DT median_NN of_IN 35_CD
          years_NNS (_( Table_NNP 1_LS )_) ._. Ten_CD patients_NNS (_( 3_CD %_NN )_) were_VBD from_IN "_'' Hospital_NNP
          San_NNP Juan_NNP de_IN Dios_NNP "_'' ;_: one-hundred_JJ thirty_CD nine_CD patients_NNS (_( 49_CD %_NN )_)
          were_VBD from_IN "_'' Hospital_NNP Simón_NNP Bolívar_NNP "_'' and_CC one_CD hundred_CD thirty_CD
          seven_CD patients_NNS (_( 48_CD %_NN )_) were_VBD from_IN the_DT "_'' Instituto_NNP de_IN Seguro_NNP
          Social_NNP "_'' ._. Fifty-eight_NNP patients_NNS were_VBD hospitalized_VBN at_IN the_DT
          time_NN of_IN enrollment_NN (_( 20_CD %_NN )_) ,_, and_CC two_CD hundred_CD twenty_CD eight_CD
          patients_NNS (_( 80_CD %_NN )_) were_VBD enrolled_VBN at_IN an_DT outpatient_NN clinic_NN ._. One_CD
          hundred_CD ninety_CD five_CD patients_NNS (_( 68_CD ._. 5_LS %_NN )_) were_VBD in_IN treatment_NN
          with_IN antiretroviral_NN medication_NN ._. Sexual_NNP preferences_NNS were_VBD
          informed_VBN in_IN 269_CD (_( 94_CD %_NN )_) patients_NNS as_IN follows_VBZ :_: in_IN males_NNS ,_,
          ninety_CD (_( 33_CD ._. 4_LS %_NN )_) were_VBD homosexual_JJ ,_, eighty-six_JJ (_( 31_CD ._. 9_CD %_NN )_) were_VBD
          bisexual_NN and_CC sixty-one_JJ (_( 22_CD ._. 7_CD %_NN )_) were_VBD heterosexual_NN ._. Of_IN the_DT
          women_NNS ,_, twenty-nine_JJ (_( 90_CD ._. 6_CD %_NN )_) were_VBD heterosexual_NN and_CC three_CD
          (_( 9_CD ._. 4_LS %_NN )_) were_VBD bisexual_NN ._. CDC_NNP staging_NN in_IN these_DT patients_NNS is_VBZ
          shown_VBN in_IN Table_NNP 1_CD ._. Viral_NNP load_NN was_VBD obtained_VBN in_IN 180_CD patients_NNS
          and_CC results_NNS varied_VBD in_IN a_DT range_NN between_IN less_JJR than_IN 50_CD and_CC 13_CD
          millions_NNS copies_NNS /_NN mL_NN ._. The_DT median_NN of_IN viral_JJ load_NN was_VBD 23_CD ,_, 420_CD
          copies_NNS /_NN mL_NN ._.
          The_DT symptoms_NNS most_RBS frequently_RB complaint_NN of_IN at_IN the_DT time_NN
          of_IN initial_JJ enrollment_NN were_VBD headaches_NNS (_( 48_CD %_NN )_) ,_, loss_NN of_IN
          weight_NN (_( 43_CD %_NN )_) ,_, and_CC mental_JJ status_NN changes_NNS (_( 38_CD %_NN )_) ._. The_DT
          frequency_NN of_IN each_DT symptom_NN is_VBZ showed_VBN in_IN Figure_NN 1_CD ._. 29_CD %_NN
          patients_NNS complaint_NN of_IN respiratory_JJ symptoms_NNS ._. 13_CD %_NN patients_NNS
          had_VBD a_DT history_NN of_IN diagnosis_NN of_IN tuberculosis_NNS ,_, and_CC 12_CD %_NN gave_VBD
          a_DT history_NN of_IN previous_JJ treatment_NN with_IN antituberculous_JJ
          drugs_NNS ._.
        
        
          Mycobacteriuminfection_NNP
          Overall_RB ,_, sixteen_NN of_IN 286_CD patients_NNS (_( 5_CD ._. 6_CD %_NN )_) were_VBD positive_JJ
          for_IN any_DT 
          Mycobacterium_NNP species_NNS by_IN acid_NN fast_RB
          staining_VBG or_CC culture_NN of_IN any_DT of_IN their_PRP$ samples_NNS ._. In_IN these_DT
          sixteen_NN cases_NNS ,_, fifteen_NN (_( 94_CD %_NN )_) were_VBD positive_JJ by_IN culture_NN ,_,
          and_CC one_CD patient_NN was_VBD detected_VBN only_RB by_IN acid_NN fast_RB bacilli_NN
          staining_VBG (_( 6_CD %_NN )_) ._. Fourteen_CD patients_NNS (_( 87_CD ._. 5_LS %_NN )_) were_VBD men_NNS and_CC two_CD
          (_( 12_CD ._. 5_LS %_NN )_) were_VBD women_NNS ._. 
          M_NNP ._. tuberculosis_NNS was_VBD identified_VBN in_IN
          four_CD cases_NNS (_( 1_CD ._. 4_LS %_NN )_) ._. 
          M_NNP ._. avium_NN was_VBD isolated_VBN in_IN thirteen_NN
          patients_NNS (_( 4_CD ._. 2_LS %_NN )_) ._. Two_CD patients_NNS presented_VBD simultaneous_JJ
          infection_NN by_IN 
          M_NNP ._. tuberculosis_NNS and_CC 
          M_NNP ._. avium_NN ._.
          Tuberculosis_NNP was_VBD diagnosed_VBN in_IN its_PRP$ pulmonary_JJ form_NN in_IN
          two_CD cases_NNS ,_, and_CC in_IN another_DT two_CD patients_NNS as_IN extrapulmonary_JJ ._.
          In_IN the_DT patients_NNS with_IN pulmonary_JJ tuberculosis_NNS ,_, the_DT AFB_NNP
          smear_NN of_IN the_DT sputum_NN was_VBD positive_JJ in_IN one_CD case_NN ,_, and_CC in_IN
          another_DT case_NN the_DT AFB_NNP smear_NN was_VBD positive_JJ in_IN his_PRP$ stool_NN
          sample_NN ._. Culture_NNP of_IN stool_NN samples_NNS was_VBD positive_JJ in_IN both_DT
          cases_NNS of_IN pulmonary_JJ and_CC in_IN one_CD case_NN of_IN extrapulmonary_JJ
          tuberculosis_NNS ._. 
          M_NNP ._. tuberculosis_NNS was_VBD detected_VBN in_IN
          different_JJ samples_NNS of_IN body_NN fluids_NNS as_RB well_RB :_: in_IN sputum_NN ,_,
          urine_NN ,_, stool_NN samples_NNS ,_, and_CC in_IN ascitic_JJ fluid_JJ (_( Table_NNP 2_LS )_) ._. All_DT
          isolates_VBZ of_IN 
          M_NNP ._. tuberculosis_NNS were_VBD sensitive_JJ to_TO
          the_DT drugs_NNS assayed_JJ :_: streptomycin_NN (_( S_NNP )_) ,_, isoniazide_NN (_( H_NNP )_) ,_,
          thioacetazone_NN (_( Th_NNP )_) ,_, ethambutol_NN (_( E_NNP )_) and_CC rifampicin_NN
          (_( R_NN )_) ._.
          The_DT only_JJ species_NNS identified_VBN as_IN non-tuberculous_JJ
          mycobacteria_NN was_VBD 
          M_NNP ._. avium_NN which_WDT was_VBD detected_VBN in_IN 13_CD
          patients_NNS (_( 4_CD ._. 2_LS %_NN )_) ._. Two_CD patients_NNS had_VBD coinfection_NN by_IN 
          M_NNP ._. tuberculosis_NNS and_CC 
          M_NNP ._. avium_NN in_IN their_PRP$ sputum_NN culture_NN ._.
          One_CD patient_NN was_VBD positive_JJ only_RB for_IN acid_NN fast_RB bacilli_NN
          staining_VBG in_IN two_CD stool_NN samples_NNS but_CC no_DT growth_NN was_VBD observed_VBN
          in_IN culture_NN tubes_NNS after_IN 16_CD weeks_NNS of_IN incubation_NN ._.
          Interestingly_RB ,_, in_IN three_CD patients_NNS the_DT direct_JJ AFB_NNP staining_VBG
          in_IN blood_NN was_VBD positive_JJ ,_, and_CC 
          M_NNP ._. avium_NN was_VBD later_RB identified_VBN in_IN
          these_DT blood_NN cultures_NNS (_( Table_NNP 3_LS )_) ._. 
          M_NNP ._. avium_NN was_VBD also_RB detected_VBN in_IN other_JJ
          clinical_JJ samples_NNS :_: urine_NN ,_, stool_NN and_CC sputum_NN (_( Table_NNP 4_LS )_) ._.
          The_DT percent_NN of_IN positive_JJ AFB_NNP smears_NNS and_CC cultures_NNS was_VBD
          greater_JJR in_IN samples_NNS of_IN sputum_NN followed_VBN by_IN the_DT samples_NNS of_IN
          stool_NN (_( Table_NNP 5_LS )_) ._. Samples_NNP of_IN urine_NN and_CC stool_NN were_VBD valuable_JJ
          to_TO identify_VB most_JJS of_IN patients_NNS with_IN a_DT 
          M_NNP ._. avium_NN infection_NN ,_, only_RB three_CD
          patients_NNS infected_VBN by_IN 
          M_NNP ._. avium_NN were_VBD identified_VBN solely_RB by_IN
          blood_NN cultures_NNS (_( Table_NNP 6_CD and_CC 7_CD )_) ._.
        
        
          Association_NNP between_IN Mycobacterium_NNP aviuminfection_NN
          and_CC clinical_JJ data_NNS
          The_DT following_VBG factors_NNS (_( Table_NNP 6_CD )_) were_VBD significantly_RB
          associated_VBN with_IN a_DT culture_NN positive_JJ for_IN 
          M_NNP ._. avium_NN infections_NNS :_: death_NN during_IN
          time_NN of_IN follow_VB up_RB (_( odds_NNS ratio_NN [_NN OR_NNP ]_NN ,_, 9_CD ._. 7_CD [_NN 95_CD %_NN CI_NNP ,_,
          2_CD ._. 8_CD -_: 32_CD ]_NN )_) ,_, loss_NN of_IN weight_NN (_( OR_NNP ,_, 8_CD [_NN 95_CD %_NN CI_NNP ,_, 1_CD ._. 6_CD -_: 54_CD ]_NN )_) ,_, and_CC
          diarrhea_NN (_( OR_NNP ,_, 3_CD ._. 9_CD [_NN 95_CD %_NN CI_NNP ,_, 1_CD ._. 1_CD -_: 14_CD ]_NN )_) ._. The_DT mean_JJ time_NN of_IN
          survival_NN during_IN the_DT study_NN was_VBD significantly_RB reduced_VBN
          in-patients_JJ infected_VBN with_IN 
          Mycobacterium_NNP avium_NN compared_VBN to_TO the_DT
          ones_NNS not_RB infected_JJ (_( 154_CD ±_NN 44_CD versus_CC 170_CD ±_NN 37_CD days_NNS ,_, p_NN =_SYM
          0_CD ._. 01_CD )_) ._. There_EX were_VBD no_DT statistically_RB significant_JJ
          differences_NNS in_IN age_NN ,_, sex_NN ,_, clinical_JJ stage_NN ,_, CD_NNP 4_CD cell_NN count_NN ,_,
          viral_JJ load_NN ,_, use_NN of_IN antiretrovirals_NNS drugs_NNS or_CC time_NN of_IN
          diagnosis_NN since_IN HIV_NNP infection_NN between_IN patients_NNS with_IN or_CC
          without_IN mycobacterial_NN infection_NN (_( Table_NNP 7_CD )_) ._. However_RB ,_, there_EX
          were_VBD no_DT patients_NNS with_IN 
          M_NNP ._. avium_NN infections_NNS in_IN clinical_JJ
          stage_NN A_DT or_CC with_IN a_DT CD_NNP 4_CD cell_NN count_NN higher_JJR than_IN 500_CD cells_NNS /_NN mm_NN
          3_CD (_( Tables_NNP 8_CD and_CC 9_CD )_) ._.
        
      
      
        Discussion_NNP
        Our_PRP$ study_NN was_VBD a_DT prospective_JJ study_NN in_IN HIV_NNP infected_JJ
        patients_NNS in_IN whom_WP an_DT indiscriminate_NN search_NN 
        Mycobacterium_NNP infection_NN was_VBD done_VBN ._.
        Clinical_NNP suspicion_NN of_IN tuberculosis_NNS existed_VBD previous_JJ to_TO
        enrollment_NN only_RB in_IN the_DT two_CD patients_NNS with_IN pulmonary_JJ 
        Mycobacterium_NNP tuberculosis_NNS infection_NN
        but_CC not_RB in_IN the_DT other_JJ two_CD patients_NNS with_IN extrapulmonary_JJ
        tuberculosis_NNS ._.
        Most_JJS of_IN 
        Mycobacterium_NNP species_NNS isolated_VBN were_VBD 
        M_NNP ._. avium_NN 
        The_DT frequency_NN that_IN we_PRP found_VBD was_VBD lower_JJR than_IN that_DT of_IN
        previously_RB reported_VBD studies_NNS for_IN 
        Mycobacterium_NNP in_IN HIV_NNP infected_JJ
        patients_NNS in_IN Colombia_NNP ._. A_DT previous_JJ study_NN at_IN the_DT "_'' Hospital_NNP San_NNP
        Juan_NNP de_IN Dios_NNP "_'' in_IN 1996_CD performed_VBN in_IN 92_CD HIV_NNP infected_JJ patients_NNS
        found_VBD a_DT prevalence_NN of_IN 8_CD %_NN for_IN 
        M_NNP ._. tuberculosis_NNS infection_NN [_NN 25_CD ]_NN ._. In_IN
        another_DT study_NN in_IN 101_CD patients_NNS in_IN Cali_NNP ,_, Colombia_NNP ,_, the_DT
        prevalence_NN was_VBD only_RB 2_CD %_NN [_NN 26_CD ]_NN ._. In_IN the_DT present_JJ study_NN it_PRP was_VBD
        1_CD ._. 4_CD %_NN ._.
        The_DT prevalence_NN of_IN non-tuberculous_JJ 
        Mycobacterium_NNP species_NNS in_IN Cali_NNP was_VBD 5_CD %_NN
        [_NN 27_CD ]_NN ,_, and_CC in_IN the_DT current_JJ study_NN it_PRP was_VBD 4_CD %_NN ._. The_DT lower_JJR
        prevalence_NN of_IN 
        M_NNP ._. tuberculosis_NNS ,_, can_MD be_VB related_VBN to_TO
        the_DT introduction_NN of_IN highly_RB active_JJ antiretroviral_NN therapy_NN
        (_( HAART_NNP )_) that_WDT was_VBD practically_RB absent_JJ in_IN the_DT previous_JJ study_NN
        in_IN Bogota_NNP in_IN 1996_CD but_CC that_DT was_VBD being_VBG used_VBN to_TO treat_VB 68_CD %_NN of_IN
        the_DT patients_NNS in_IN the_DT current_JJ study_NN ._. Our_PRP$ results_NNS are_VBP also_RB
        different_JJ to_TO the_DT ones_NNS reported_VBD in_IN a_DT General_NNP Hospital_NNP ,_, AIDS_NNP
        reference_NN center_NN ,_, in_IN Rio_NNP de_IN Janeiro_NNP ,_, Brazil_NNP [_NN 28_CD ]_NN where_WRB
        mycobacteria_NN were_VBD recovered_VBN from_IN 20_CD ._. 6_CD %_NN (_( 313_CD of_IN 1_CD ,_, 517_CD )_) of_IN
        all_DT patients_NNS ,_, and_CC 
        M_NNP ._. tuberculosis_NNS was_VBD identified_VBN in_IN
        94_CD ._. 2_LS %_NN (_( 295_CD /_NN 313_CD )_) ,_, and_CC non-tuberculous_JJ mycobacteria_NN in_IN 5_CD ._. 8_CD %_NN
        (_( 18_CD /_NN 313_CD )_) ._. Our_PRP$ results_NNS suggest_VBP that_IN when_WRB antiretroviral_NN
        therapy_NN is_VBZ introduced_VBN the_DT relative_JJ frequency_NN of_IN 
        M_NNP ._. tuberculosis_NNS infections_NNS is_VBZ reduced_VBN
        and_CC the_DT one_CD of_IN 
        M_NNP ._. avium_NN infections_NNS increases_NNS [_NN 28_CD ]_NN
        ._.
        We_PRP found_VBD that_IN 
        Mycobacterium_NNP avium_NN infection_NN was_VBD
        related_VBN to_TO symptomatic_JJ diarrhea_NN and_CC greater_JJR mortality_NN as_IN
        has_VBZ been_VBN reported_VBN previously_RB [_NN 29_CD ]_NN ._. Our_PRP$ study_NN shows_VBZ that_DT
        frequency_NN of_IN isolation_NN of_IN 
        M_NNP ._. avium_NN was_VBD greater_JJR in_IN urine_NN and_CC
        stool_NN samples_NNS ._. This_DT emphasizes_VBZ the_DT need_NN to_TO take_VB multiple_JJ
        body_NN fluid_JJ samples_NNS in_IN order_NN to_TO enhance_VB the_DT opportunity_NN of_IN
        isolation_NN increasing_VBG the_DT microbiologic_JJ diagnostic_JJ
        sensitivity_NN ._. Interestingly_RB ,_, we_PRP found_VBD that_DT blood_NN AFB_NNP smears_NNS
        can_MD be_VB useful_JJ to_TO rapidly_RB confirm_VB a_DT clinical_JJ diagnosis_NN of_IN
        disseminated_VBN 
        Mycobacterium_NNP avium_NN infection_NN ._.
        In_IN the_DT present_JJ study_NN there_EX were_VBD no_DT resistant_JJ strains_NNS of_IN 
        M_NNP ._. tuberculosis_NNS found_VBD ._. In_IN a_DT previous_JJ
        survey_NN in_IN Colombia_NNP it_PRP was_VBD found_VBN that_IN 
        M_NNP ._. tuberculosis_NNS isolates_VBZ among_IN new_JJ
        cases_NNS in_IN patients_NNS without_IN HIV_NNP infection_NN showed_VBD resistance_NN
        in_IN 9_CD ._. 5_CD %_NN (_( 4_CD of_IN 42_CD )_) [_NN 30_CD ]_NN ._.
      
      
        Conclusions_NNP
        Our_PRP$ study_NN found_VBD that_IN 5_CD %_NN of_IN HIV_NNP infected_JJ patients_NNS in_IN
        Bogota_NNP were_VBD infected_VBN with_IN 
        Mycobacteria_NNP and_CC that_IN 
        M_NNP ._. Avium_NNP was_VBD the_DT predominant_NN species_NNS ._.
        It_PRP becomes_VBZ evident_JJ the_DT need_NN to_TO improve_VB the_DT preventive_JJ
        measures_NNS and_CC prompt_VB treatment_NN of_IN this_DT type_NN of_IN opportunistic_JJ
        infection_NN in_IN the_DT HIV_NNP infected_JJ individuals_NNS ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD
      
    
  
